Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HealthEquity's revenue for the
three
months ended in Apr. 2026 was €303 Mil.
Its revenue for the trailing twelve months (TTM) ended in Apr. 2026 was €1,144 Mil.
HealthEquity's Revenue per Share for the
three
months ended in Apr. 2026 was €3.57.
Its Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was €13.22.
Good Sign:
HealthEquity Inc has shown predictable revenue and earnings growth.
During the past 12 months, the average Revenue per Share Growth Rate of HealthEquity was 10.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 10.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 21.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, HealthEquity's highest 3-Year average Revenue per Share Growth Rate was 37.70% per year. The lowest was -35.30% per year. And the median was 26.20% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
HealthEquity Revenue Related Terms
HealthEquity Revenue Historical Data
* Premium members only.
The historical data trend for HealthEquity's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, HealthEquity's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HealthEquity Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, HealthEquity's Revenue distribution charts can be found below:
* The bar in red indicates where HealthEquity's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,144 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HealthEquity (FRA:2HE) has a Revenue of €1,144 Mil as of Apr. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on HealthEquity and its competitors.
Is HealthEquity's Revenue too high?
HealthEquity's current Revenue is €1,144 Mil. Overall, HealthEquity has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HealthEquity's Revenue compare to TEM and TXG?
HealthEquity's Revenue of €1,144 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on HealthEquity and its competitors. HealthEquity's current Revenue is €1,144 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HealthEquity stock overvalued right now?
Based on GuruFocus' analysis, HealthEquity (FRA:2HE) is currently considered Fairly Valued. The stock's GF Value™ is €90.47, compared to a current price of €87.50 — trading 3.3% below its estimated fair value. The current Revenue is €1,144 Mil. HealthEquity's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For HealthEquity (FRA:2HE), the current Revenue is €1,144 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HealthEquity (FRA:2HE) Overvalued in 2026?
Based on GuruFocus' analysis, HealthEquity stock appears to be undervalued.
The current stock price of €87.50 is trading 3.3% below its estimated GF Value™ of €90.47.
GuruFocus considers HealthEquity to be Fairly Valued.
Key valuation signals for FRA:2HE:
Revenue: €1,144 Mil
GF Value™: €90.47 vs. price of €87.50 (3.3% below fair value)
No single metric tells the full story. See the FRA:2HE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
97GF Score
Get the complete analysis for FRA:2HE
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2HE has been successfully added to your 
